1. What did you like most about this piece? (select all that apply)

2. Having read this article, do you think daratumumab could be a valuable new treatment option for refractory and relapsing multiple myeloma patients?

3. How would you summarise daratamumab as a treatment? (select all that apply)

4. Which areas do you feel you require more information to help your understanding of daratumumab? (select all that apply)

5. Having read this article, will your prescribing of daratumumab in appropriate patients change?